Next-generation sequencing (NGS) and microarray technologies are essential resources for investigating the genomic and molecular underpinnings of cancer formation, progression, and clinical outcomes. The primary objective of the Cancer Genomics Shared Resource (CGSR) is to maximize the scientific and clinical impact of research by Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) members. This is accomplished by providing rapid and cost-effective access to state-of-the-art genomic technologies, while creating a unifying environment that cultivates scientific awareness, education, and collaboration. The CGSR supports the WFBCCC's mission by providing cancer-prioritized access to comprehensive microarray and NGS technologies and offers seamless data flow through to the Biostatistics and Bioinformatics Shared Resource - for bioinformatics support. In October 2014, at the instigation of Director Pasche, the former Microarray Core Laboratory (2002-2014; which received a score of ?excellent? in the prior critique) was renamed the Cancer Genomics Shared Resource to reflect the integration of the WFBCCC's microarray core competencies with the NGS expertise of the Center for Genomics and Personalized Medicine Research. This new joint-Center partnership reflects the strategic plans of the WFBCCC and the Wake Forest School of Medicine (WFSOM), as well as supporting priority recommendations of the WFSOM Centers and Cores Advisory Committee. The CGSR provides cutting-edge genomic services, prioritizes cancer-specific research, creates an optimal environment for the Institution's rapidly developing precision medicine initiative, and seamlessly integrates with other key Shared Resources within the WFBCCC to promote integrated, high-quality workflows for cancer genomics research. The CGSR is led by Co-Directors Lance Miller, Ph.D., and Greg Hawkins, Ph.D., who have established records in cancer genomics research, and is operated by four experienced technicians (two at 100% effort, one at 50% effort and one at 5% effort). A bioinformatician devotes 30% of effort to CGSR daily operations. In the most recent grant year (11/01/14-10/31/15), the CGSR operated at 80-90% FTE utilization to provide 1,144 services to 20 investigators, 75% of which were WFBCCC investigators. Compared to previous years, the CGSR doubled its service output and increased its cancer-specific service output by approximately 50%. The CGSR directly contributes to the scientific achievements of WFBCCC investigators by generating high-quality and cost-effective data that will translate into new discoveries, publications, grant awards, and grant applications. Further development of CGSR's role in supporting the development and productivity of WFBCCC Disease-Oriented Teams and the continued development of seamless workflows across Shared Resources are expected to enhance translational genomics initiatives at the WFBCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-46
Application #
10092987
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-02-01
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Xiao, Jiajie; Melvin, Ryan L; Salsbury Jr, Freddie R (2018) Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning. J Biomol Struct Dyn :1-18
Mao, Chengqiong; Zhao, Yan; Li, Fang et al. (2018) P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release 286:289-300
Diaz-Garelli, Jose-Franck; Wells, Brian J; Yelton, Caleb et al. (2018) Biopsy Records Do Not Reduce Diagnosis Variability in Cancer Patient EHRs: Are We More Uncertain After Knowing? AMIA Jt Summits Transl Sci Proc 2017:72-80
Wang, Mingxuan; Chen, Haiqin; Ailati, Aisikaer et al. (2018) Substrate specificity and membrane topologies of the iron-containing ?3 and ?6 desaturases from Mortierella alpina. Appl Microbiol Biotechnol 102:211-223
Westcott, Marlena M; Clemens, Elene A; Holbrook, Beth C et al. (2018) The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine 36:1174-1182
Ruiz, Jimmy; Miller, Antonius A; Tooze, Janet A et al. (2018) Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol :
Levine, Edward A; Votanopoulos, Konstantinos I; Shen, Perry et al. (2018) A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. J Am Coll Surg 226:434-443
Addington, Elizabeth L; Sohl, Stephanie J; Tooze, Janet A et al. (2018) Convenient and Live Movement (CALM) for women undergoing breast cancer treatment: Challenges and recommendations for internet-based yoga research. Complement Ther Med 37:77-79
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681

Showing the most recent 10 out of 548 publications